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ABSTRACT
Cariprazine is a dopamine D3-preferring 
D3/D2 receptor partial agonist in late-stage 
clinical development for the treatment of 
schizophrenia, as well as for bipolar disorder 
(manic/mixed and depressive episodes), and 
as an adjunctive agent for the treatment of 
major depressive disorder. Four phase 2 or 
3, 6-week, randomized controlled trials in 
acute schizophrenia have been completed 
and reported as poster presentations or in 
press releases by the manufacturer. Superiority 
over placebo on the Positive and Negative 
Syndrome Scale total score was evidenced 
for cariprazine in daily doses of 1.5, 3.0, 
4.5, 6.0, 1.5–4.5, 3.0–6.0, and 6.0–9.0 mg. 
A randomized controlled trial for the 
prevention of relapse of schizophrenia is 
ongoing. In short-term, randomized controlled 
trials, cariprazine does not appear to adversely 
impact metabolic variables, prolactin, or the 
electrocardiogram (ECG) QT interval. In the 
fixed-dose study of cariprazine that tested 
1.5, 3.0, and 4.5 mg/day, the most commonly 
encountered adverse events were insomnia, 
extrapyramidal disorder, sedation, akathisia, 
nausea, dizziness, vomiting, anxiety, and 
constipation. However, the differences in 
incidence versus placebo for these events were 
generally small. If approved by regulatory 
authorities, cariprazine would join aripiprazole 
as the second dopamine receptor partial 
agonist antipsychotic available for clinical 
use. Cariprazine differs from aripiprazole in 
terms of dopamine D3 receptor selectivity. 
Further studies would be helpful to discern 
the distinguishing features of cariprazine from 
other second-generation antipsychotics. 
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variables than some of the older agents in the 
class. These “metabolically-friendlier” second-
generation antipsychotics differ in several 
important ways, including requirements for 
titration, dosing frequency, meal requirements, 
sedation profile, extrapyramidal symptoms 
(EPS)/akathisia profile, effects on prolactin, 
potential effects on the electrocardiogram (ECG) 
QT interval, and the availability of additional 
formulations and indications [2]. 
Cariprazine is a new second-generation 
antipsychotic in late-stage of clinical 
deve lopment  fo r  the  t r ea tment  o f 
schizophrenia, as well as for bipolar disorder 
(manic/mixed and depressive episodes) and 
as an adjunctive agent for the treatment of 
major depressive disorder. The intent of this 
review is to describe the efficacy, tolerability, 
and potential place in therapy of cariprazine 
for the treatment of schizophrenia. 
A PubMed search was conducted on October 
31 2012 using the search terms “cariprazine,” 
“RGH-188,” and “RGH 188” without any 
date or language restrictions. The resulting 
15 publications and their reference lists were 
then specifically examined for primary sources 
of information with emphasis on the use of 
cariprazine in persons with schizophrenia. 
A query of the ClinicalTrials.gov website on 
October 31 2012 yielded 18 separate records 
and provided additional information regarding 
registered trials of cariprazine. The abstract 
books for the annual scientific meetings of 
the American Psychiatric Association (2008–
2012) [3–7], Institute on Psychiatric Services of 
the American Psychiatric Association (2008–
2012) [8–12], New Clinical Drug Evaluation 
Unit (2008–2012) [13–17], and American 
College of Neuropsychopharmacology (2008–
2011) [18–21] were also examined and yielded 
additional relevant data that have not yet 
been published as full reports in peer-refereed 
INTRODUCTION
A major challenge in the treatment of 
schizophrenia is the heterogeneity of 
antipsychotic response, both in terms of 
efficacy and tolerability [1]. The adage of “one 
size fits all” has no place in the contemporary 
management of this chronic and disabling 
disorder. Thus, when new antipsychotic 
medications become available, an individual 
with schizophrenia will have another option 
to try that may be more helpful for them 
in terms of reducing symptoms, be more 
easily tolerated, lead to improved adherence, 
and ultimately lead to superior outcomes. 
Unfortunately, there is no available technique 
that will predict which patient will respond to 
what antipsychotic and, thus, empirical trials 
of one medication after another is the usual 
course of events. 
The antipsychotics themselves have differing 
pharmacodynamic properties that usually 
translate to small differences in efficacy and 
large differences in tolerability profiles when 
comparing groups of individuals. With regard to 
the tolerability differences, each antipsychotic 
option has its own profile of most commonly 
encountered adverse events, and this can be a 
starting point to tailor choices consistent with 
an individual’s values and preferences, assuming 
adequate efficacy for that person [1]. 
In the US, several first-line, second-generation 
antipsychotics are now available as generic 
products – risperidone, olanzapine, quetiapine 
(in the immediate-release formulation), and 
ziprasidone. The other available second-
generation antipsychotics, aripiprazole, 
paliperidone, iloperidone, asenapine, and 
lurasidone, are branded and relatively more 
expensive, but represent additional treatment 
options that together with ziprasidone have 
a smaller impact on weight and metabolic 
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PHARMACODYNAMICS AND 
PHARMACOKINETICS
Cariprazine is a dopamine D3-preferring, 
D3/D2 receptor partial agonist. The in vitro 
binding of cariprazine was highest for human 
dopamine D3 receptors (Ki 0.085 nM), followed 
by affinity for both D2L and D2S subtypes of 
human D2 receptors (Ki 0.49 nM and 0.69 nM, 
respectively) (Table 2 in [24]). Aripiprazole is 
also a dopamine receptor partial agonist but 
although it shares with cariprazine similar D2 
receptor binding affinity, cariprazine has more 
robust D3 antagonist–partial agonist affinity and 
3- to 10-fold greater D3 versus D2 selectivity [24]. 
The D3 receptor is an autoreceptor that controls 
the phasic, but not tonic, activity of dopamine 
journals. Whenever possible, reproductions 
of the poster presentations were obtained 
in digital PDF format from the authors. 
Press releases from the manufacturer were 
also reviewed for preliminary clinical trial 
results that have not yet been presented at 
scientific meetings. A similar search strategy 
has been used by the author in other reviews 
of cariprazine, including a companion review 
regarding cariprazine for the treatment 
of bipolar disorder [22], and a systematic 
review with emphasis on the chemistry, 
pharmacodynamics, and pharmacokinetics of 
cariprazine [23]. A complete list of all clinical 
trials for cariprazine as registered on the 
ClinicalTrials.gov website is available in the 
latter review [23].
Table 1  Summary of double-blind, randomized ecacy trials of cariprazine for schizophrenia, as conducted by the 
manufacturer. All are 6 weeks in duration unless otherwise noted
Study Phase N Cariprazine daily dose/
dose ranges (N)







2 392 1.5–4.5 mg (128);  
6.0–12.0 mg (134)
None 130 Unpublished. Presented 
as a poster. 
RGH-MD-16 
[38]
2 732 1.5 mg (145); 3.0 mg 
(147); 4.5 mg (148)
Risperidone 4.0 mg 
(141)
151 Unpublished. Presented 
as a poster. An open-label 
extension to this study was 
also completed and data 
presented as a poster [41].
RGH-MD-04 
[39]
3 617 3.0 mg (ND); 6.0 mg 
(ND)
Aripiprazole 10 mg 
(ND)
ND Unpublished. Limited 




3 446 3.0–6.0 mg (ND); 
6.0–9.0 mg (ND)
None ND Unpublished. Limited 




3 ~900 3.0–9.0 mg (NA) None NA Ongoing long-term relapse 
prevention study. See 
NCT01412060 on the 
ClinicalTrials.gov website. 
ere is one additional study that was conducted in Japan and was a 2-week phase 2 exploratory study [42]. Results have not 
been publically disclosed 
NA not applicable, ND not disclosed
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neurons and is thought to mediate behavioral 
abnormalities elicited by glutamate/N-Methyl-
D-aspartic acid (NMDA) receptor blockade [25]. 
Animal studies have demonstrated pro-cognitive 
effects potentially attributable to dopamine D3 
preferring agents [26, 27].
Cariprazine also has high binding affinity for 
human serotonin 5-HT2B receptors (Ki 0.58 nM) 
(Table 2 in [24]). Activity at these receptors may 
modulate dopamine release in the nucleus 
accumbens [28]. Cariprazine has more moderate 
affinity for human 5-HT1A receptors (Ki 3 nM) 
and acts as a partial agonist at this receptor [24]. 
Theoretically, this may be associated with 
beneficial effects on negative symptoms and 
cognitive dysfunction, as observed in preclinical 
studies [29, 30]. Affinity at other receptors is 
weaker. This includes human 5-HT2A (Ki 19 nM), 
histamine H1 (Ki 23 nM), 5-HT7 (111 nM), and 
5-HT2C (134 nM) receptors. Low affinity was 
observed for all tested adrenergic receptors [24]. 
This profile differs from that of aripiprazole, where 
aripiprazole bound more potently than cariprazine 
to rat striatal dopamine D2, human and rat 
5-HT2A, 5-HT2C, and adrenergic receptors [24]. 
In a study of male subjects with 
schizophrenia, positron emission tomography 
(PET) scans of dorsal striatal regions (caudate 
nucleus and putamen) and ventral striatum 
(nucleus accumbens) showed after 14 days 
Table 2  Treatment-emergent adverse events with an incidence at least 5% for any of the active treatment arms and at least 




1.5 mg/day  
(n = 145)
3.0 mg/day  
(n = 146)




% % NNH % NNH % NNH % NNH
Insomnia 7 10 34 16 12 16 12 15 13
Extrapyramidal disorder 5 9 25 9 25 12 15 13 13
Sedation 3 5 50 5 50 8 20 11 13
Akathisia 5 9 25 10 20 8 34 9 25
Nausea 3 5 50 8 20 8 20 6 34
Dizziness 2 3 100 2 ND 6 25 6 25
Vomiting 3 3 ND 6 34 5 50 3 ND
Anxiety 3 4 100 6 34 5 50 2 NA
Constipation 3 10 15 6 34 5 50 9 17
Tremor 3 3 ND 4 100 2 NA 7 25
Weight increased 1 2 100 3 50 0 NA 5 25
As noted in the text regarding study RGH-MD-03 [37], incidence of akathisia was 1% for subjects receiving placebo, 10% 
for cariprazine 1.5–4.5 mg/day, and 9% for cariprazine 6.0–12.0 mg/day, yielding NNH values versus placebo of 12 and 
13 for low-dose and high-dose cariprazine, respectively. Incidence of extrapyramidal disorder was 5% for subjects receiving 
placebo, 6% for cariprazine 1.5–4.5 mg/day, and 10% for cariprazine 6.0–12.0 mg/day, yielding NNH values versus. placebo 
of 100 and 20 for low-dose and high-dose cariprazine, respectively
NA not applicable as placebo rate is greater than drug rate, ND no dierence from placebo, NNH number needed to harm
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of cariprazine 1.5 mg/day, dopamine D2/D3 
receptor occupancy of 69% in the caudate 
nucleus, 69% in the nucleus accumbens, and 
75% in the putamen [31, 32]. After 14 days of 
cariprazine 3 mg/day, maximum occupancy 
(≥90%) was observed [31, 32]. 
The pharmacokinetics of cariprazine was 
tested in small short-term studies in both 
healthy volunteers [33] and in subjects with 
schizophrenia [34, 35], with similar results [35]. 
Maximum concentration is observed in 3−4 h 
under fasting conditions, with food causing a 
slight delay but no significant effect on the extent 
of absorption. The mean half-life for cariprazine 
was 2–5 days over a dose range of 1.5–12.5 mg in 
the subjects with schizophrenia [34]. Cariprazine 
is metabolized by cytochrome P450 3A4 and, to 
a lesser extent, by cytochrome P450 2D6 [36]. 
Following multiple administrations, there was 
marked accumulation in plasma concentrations 
for cariprazine and its metabolites, desmethyl-
cariprazine and didesmethyl-cariprazine. 
Systemic exposure to desmethyl-cariprazine 
was 30–40% of cariprazine, and was dose 
proportional. Didesmethyl-cariprazine’s half-life 
is substantially longer than that for cariprazine, 
and in the study of healthy volunteers the half-life 
was observed to be 2–3 weeks [33]; thus, systemic 
exposure to didesmethyl-cariprazine was several 
times higher than that for cariprazine [34, 35]. 
Steady state was achieved within the dosing 
duration of 3 weeks for cariprazine and 
desmethyl-cariprazine, but not for didesmethyl-
cariprazine [34, 35]. 
SHORT-TERM CLINICAL TRIALS
Overview
Results from two phase 2 and two phase 3, short-
term, randomized controlled trials of cariprazine 
in subjects with schizophrenia have been 
reported in posters at scientific meetings [37, 38] 
and in a press release from the manufacturer [39]. 
Table 1 [37–42] provides an overview of 
studies RGH-MD-03 [37], RGH-MD-16 [38], 
RGH-MD-04 [39], and RGH-MD-05 [39]. In all 
of the studies, subjects could receive up to 6 
weeks of randomized treatment. The primary 
efficacy measure was the Positive and Negative 
Syndrome Scale (PANSS) total score; the primary 
outcome was change from baseline on the 
PANSS total score at the 6-week endpoint. 
Figure 1 [37–39] provides an overview of the 
PANSS total score difference from placebo at 
endpoint for the four studies. All cariprazine 
treatment arms were statistically superior to 
placebo on the primary outcome, with the 
exception of the high-dose treatment arm 
(6.0–12.0 mg/day) in RGH-MD-03, the proof-
of-concept phase 2 study that enrolled the least 
number of subjects.
RGH-MD-03
This flexible-dose study was conducted in 
34 US sites [37]. Inclusion criteria included a 
diagnosis of schizophrenia, current psychotic 
episode less than 4 weeks in duration, 18–65 
years of age, PANSS total score of 80–120, and 
a Clinical Global Impressions-Severity (CGI-S) 
score of ≥4. After up to 7 days of a washout off 
medications in an inpatient setting, 392 subjects 
were randomized (safety population included 
389 subjects) to “low-dose” cariprazine, 
“high-dose” cariprazine, or placebo. Subjects 
randomized to low-dose cariprazine received 1.5 
mg/day on days 1 and 2, 1.5–3.0 mg/day on days 
3 and 4, and 1.5–4.5 mg/day as of day 5. Subjects 
randomized to high-dose cariprazine received 
1.5 mg/day on days 1 and 2, 3.0 mg/day on days 
3 and 4, 3.0–6.0 mg/day on days 5 and 6, 3.0–9.0 
mg/day on days 7 and 8, and 6.0–12.0 mg/day as 
of day 9. Hospitalization was mandatory during 
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screening and the first 3 weeks of double-blind 
treatment. Mean age of subjects ranged from 
40 to 42 years across the three treatment arms; 
male gender ranged from 76% to 83%; body 
mass index (BMI) ranged from 28 to 29 kg/m2; 
and baseline PANSS total score ranged from 94 to 
96. A total of 46% patients discontinued the trial 
prematurely (same proportion for all treatment 
arms). Adverse events leading to discontinuation 
were 15%, 9%, and 8% for placebo, low-dose, 
and high-dose groups, respectively; primarily 
for worsening of schizophrenia. For the 
primary efficacy parameter, the overall P value 
comparing the three treatment groups was 
not statistically significant (P = 0.10). Pairwise 
comparison between each cariprazine dose 
group and placebo yielded nominal (without 
multiplicity adjustment) significant superiority 
for the low-dose group but not for the high-dose 
group. Low-dose cariprazine showed nominal 
(without multiplicity adjustment) statistical 
superiority versus placebo in PANSS negative 
score starting at week 1 and continuing until the 
end of the study. Treatment-emergent adverse 
events with an incidence of at least 10% for any 
of the cariprazine treatment arms and at least 
twice that for placebo were akathisia (low-dose 
cariprazine: 10%, high-dose cariprazine: 9%, 
placebo: 1%) and extrapyramidal disorder (low-
dose cariprazine: 6%, high-dose cariprazine: 
10%, placebo: 5%). No clinically meaningful 
changes in fasting serum glucose, serum lipid 
levels, and prolactin level were reported. 
RGH-MD-16
This fixed-dosed study was conducted 
internationally and 38% of subjects were 
enrolled in the US [38]. Inclusion criteria 
included a diagnosis of schizophrenia, 
Fig. 1  Cariprazine ecacy outcomes: Positive and Negative Syndrome Scale total score dierence from placebo, by study 
and daily dose, for four 6-week, randomized controlled trials. All cariprazine arms, except for 6.0–12.0 mg in RGH-MD-03, 
were statistically signicantly superior to placebo (see text). Active controls were used in RGH-MD-16 (risperidone 4.0 mg/
day, change from placebo approximately 15 points as measured from Fig. 1 in [38]) and RGH-MD-04 (aripiprazole, change 
not disclosed in [39]). Last observation carried forward was used in RGH-MD-03 and RGH-MD-04. Mixed models for 





















1.5 mg 3.0 mg
RGH-MD-03 [37] RGH-MD-16 [38] RGH-MD-04 [39] RGH-MD-05 [39]
4.5 mg 6.0 mg
1.5–4.5 mg 3.0–6.0 mg 6.0–9.0 mg 6.0–12.0 mg
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current psychotic episode less than 2 weeks in 
duration, 18–60 years of age, PANSS total score 
of 80–120, a rating of ≥4 (moderate or higher) 
on at least two of the four PANSS positive 
items of delusions, hallucinatory behavior, 
conceptual disorganization, and suspiciousness/
persecution, and a CGI-S score of ≥4. A total 
of 732 subjects (729 in the safety population) 
were randomized to cariprazine 1.5, 3.0, or 
4.5 mg/day, risperidone 4.0 mg/day, or placebo. 
The starting dose of cariprazine was 1.5 mg/day; 
dosages increased in increments of 1.5 mg/day 
for subjects randomized to 3 mg/day 
(day 2) or 4.5 mg/day (day 3). The starting dose 
of risperidone was 2 mg/day and titrated to 
4 mg/day on day 3. Subjects were required to 
be hospitalized during the washout/screening 
period and for the first 4 weeks of double-blind 
treatment; on day 28 and thereafter, patients 
could be discharged if their CGI-S score was 
no greater than 3, posed no significant risk of 
suicide or violent behavior, and were deemed 
ready for discharge. Mean age of subjects ranged 
from 36 to 37 years across the five treatment 
arms; male gender ranged from 64% to 73%; 
white race ranged from 48% to 53%; mean 
duration of schizophrenia ranged from 11 to 
12 years; and baseline PANSS total score ranged 
from 97 to 98. A total of 36% discontinued 
the trial prematurely (range 28–48% across 
the treatment arms). Adverse events leading to 
discontinuation were 15, 10, 6, 8, and 9% for 
placebo, cariprazine 1.5, 3.0, and 4.5 mg/day, 
and risperidone, respectively; usually for 
worsening of schizophrenia, psychotic disorder, 
and psychotic behavior. On PANSS total score, 
statistically significant improvements were 
seen for each cariprazine dose group and for 
risperidone relative to placebo. Significant 
improvement at week 6 for cariprazine and 
risperidone versus placebo was also seen on 
the CGI-S. Cariprazine (and risperidone) 
were statistically significantly superior to 
placebo on positive (PANSS Positive subscale) 
and negative (PANSS Negative subscale and 
Negative Symptom Assessment [NSA-16]) 
symptoms of schizophrenia. Clinical Global 
Impressions-Improvement (CGI-I) scores at 
week 6 demonstrated superior improvement 
for each of the cariprazine treatment arms 
and for risperidone versus placebo. In general, 
improvements on each of the efficacy outcomes 
were numerically higher for cariprazine 
4.5 mg/day, followed by 3.0 and 1.5 mg/day. 
The efficacy outcomes were numerically highest 
for risperidone. Treatment-emergent adverse 
events with an incidence at least 5% for any of 
the cariprazine treatment arms and at least twice 
that for placebo were insomnia, extrapyramidal 
disorder, sedation, akathisia, nausea, dizziness, 
vomiting, anxiety, and constipation. None of 
the treatment-emergent adverse events yielded 
number-needed-to-harm (NNH) values <10 
for any of the cariprazine doses tested; see 
Table 2 [37, 38]. EPS-related adverse events (as 
opposed to the more restrictive adverse event 
term “extrapyramidal disorder”) were reported 
by 21%, 22%, 22%, and 29% of cariprazine 
1.5, 3.0, and 4.5 mg/day, and risperidone 
subjects, respectively, versus 13% for placebo 
subjects. This yields a NNH versus placebo 
of 13, 12, 12, and 7 for cariprazine 1.5, 3.0, 
and 4.5 mg/day, and risperidone subjects, 
respectively. No clinically meaningful changes 
in metabolic variables, prolactin elevation, or 
QTc prolongation (>500 msec) were observed 
for cariprazine. Potentially clinically significant 
weight gain (≥7% increase from baseline) was 
greater for risperidone (16.7%) than cariprazine 
(8.5%, 10.7%, and 4.9% for 1.5, 3.0, and 4.5 
mg/day, respectively) or placebo (2%), yielding 
a NNH versus placebo of 16, 12, 35, and 7 
for cariprazine 1.5, 3.0, and 4.5 mg/day, and 
risperidone subjects, respectively.
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RGH-MD-04
This fixed-dosed study was conducted 
internationally [39]. Inclusion criteria included 
a diagnosis of schizophrenia, 18–60 years of age, 
and a PANSS total score of 80–120. A total of 617 
subjects were randomized to one of the following 
treatments arms: cariprazine 3.0 mg/day, 
cariprazine 6.0 mg/day, aripiprazole 10 mg/day, 
or placebo. Subjects were required to be 
hospitalized during the washout period and for 
the first 4 weeks of the double-blind treatment; 
afterwards they could be discharged from the 
hospital as determined by the site investigator 
and based on the patient’s clinical status. A total 
of 33% of patients discontinued prematurely. 
Statistically significant improvement in PANSS 
total score was observed in each of the cariprazine 
dose groups relative to placebo. Moreover, 
the change from baseline in PANSS total score 
was statistically significant at every time point 
starting at week 1 for cariprazine 6.0 mg/day and 
week 3 onwards for the cariprazine 3.0 mg/day. 
Statistically significant improvements were also 
seen in the aripiprazole group relative to placebo 
in the PANSS total score at each week. The most 
common adverse events (incidence of at least 
10%) observed in any treatment were akathisia, 
insomnia, and headache.
RGH-MD-05
This fixed-flexible dose study was conducted 
internationally [39]. Inclusion criteria included 
a diagnosis of schizophrenia, 18–60 years of age, 
and a PANSS total score of 80–120. A total of 
446 subjects were randomized to one of the following 
treatment arms: cariprazine 3.0–6.0 mg/day, 
cariprazine 6.0–9.0 mg/day, or placebo. Subjects 
were required to be hospitalized during the 
washout period and for the first 4 weeks of the 
double-blind treatment; afterwards they could be 
discharged from the hospital as determined by 
the site investigator and based on the patient’s 
clinical status. A total of 39% of  patients 
discontinued prematurely. Statistically significant 
improvement in PANSS total score was observed 
in each of the cariprazine dose groups relative to 
placebo. The change from baseline was statistically 
significant at every time point starting at week 1 
for cariprazine 6.0–9.0 mg/day and week 2 onward 
for cariprazine 3.0–6.0 mg/day. The most common 
adverse events (incidence of at least 10%) observed 
in any treatment group were akathisia, headache, 
insomnia, restlessness, and extrapyramidal disorder.
LONG-TERM CLINICAL TRIALS
Additional safety and tolerability data is available 
from a 48-week, open-label, extension study, 
RGH-MD-17 [41]. Subjects were required to have 
completed RGH-MD-16 [38] and be classified as 
a responder (defined as having a CGI-S score no 
greater than 3 and a reduction in their PANSS 
total score of at least 20% relative to baseline), 
and be stable and eligible to continue as 
outpatients. Exclusion criteria included ongoing, 
uncontrolled, clinically significant adverse events 
or extrapyramidal symptoms not adequately 
controlled by medication; or clinically significant 
abnormal vital signs, clinical laboratory values, 
ECG results, ophthalmology assessment, or 
physical examination. There was a medication-
free screening period of up to 7 days. Cariprazine 
was initiated at 1.5 mg/day and up-titrated in 
1.5-mg dose increments to a maximum of 4.5 mg/
day, depending on response and tolerability. The 
dose could be decreased at any time if tolerability 
issues arose. A total of 97 subjects were enrolled 
in the extension study and 93 patients received at 
least one dose of cariprazine (safety population). 
Of the 93 subjects in the safety population, 
53 subjects had been randomized to cariprazine 
in the lead-in study compared to 15 to placebo, 
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and 25 to risperidone. Mean age was 34.5 years; 
male gender 68%; white race 56%; mean BMI 
25.0 kg/m2. A total of 50.5% discontinued the 
trial prematurely; reasons include withdrawal 
of consent (17.2% of all subjects), adverse 
events (10.8%), protocol violation (9.7%), lost 
to follow-up (7.5%), insufficient therapeutic 
response (3.2%), and other reasons (2.2%). 
Mean duration of treatment was 222 days. 
Cariprazine 4.5 mg/day was the final dose for 
70% of the subjects and the model dose for 
68%. The most common treatment-emergent 
adverse events (incidence of at least 10%) were 
akathisia (14%), insomnia (14%), and weight 
gain (12%). Mean changes in clinical laboratory 
values were generally small. There was no signal 
for treatment-emergent hepatic abnormalities. 
Mean prolactin levels decreased from baseline. 
No clinically significant trends or changes were 
noted on most metabolic variables, but insulin 
showed an increasing trend from baseline. Mean 
body weight increased by 1.87 kg from a lead-in 
baseline mean of 71.26 kg. Increase in weight of 
at least 7% from baseline was observed in 33% of 
subjects; decrease in weight by at least 7% from 
baseline was observed in 8% of subjects. Although 
mean and median changes in blood pressure and 
pulse rate parameters were small, orthostatic 
hypotension while changing from the supine to 
standing position were noted in 25% of subjects. 
No signal was observed for abnormalities in the 
ECG QT interval. The rate of treatment-emergent 
parkinsonism (Simpson Angus Scale total 
score >3) was 8.6% and was similar to the rate 
observed for cariprazine in the lead-in study (8.2–
10.3%) [38, 41]. The rate of treatment-emergent 
akathisia (Barnes Akathisia Scale score >2) was 
17.2% and was higher than the rate observed in 
the lead-in study (11.0–15.1%) [38, 41]. There 
were no discontinuations because of treatment-
emergent movement disorder-related adverse 
events. There were no treatment-emergent 
adverse events related to suicidal ideation or 
behavior. There was no signal for treatment-
emergent ophthalmological abnormalities. 
RANDOMIZED CONTROLLED 
TRIALS IN PROGRESS
Table 1 notes an ongoing trial, RGH-MD-06, a 
long-term relapse prevention study [40]. As per 
the study registration on the ClinicalTrials.gov 
website, subjects with schizophrenia, 18–60 years 
of age, and with a PANSS total score between 
70 and 120 are eligible, and would receive cariprazine 
3.0–9.0 mg/day during an open-label phase prior to 
randomization to cariprazine or placebo. The study 
is being conducted internationally.
OVERALL PLACE OF CARIPRAZINE 
IN THERAPY
Cariprazine represents a new treatment option for 
schizophrenia. Efficacy was established in the dose 
range of 1.5–9.0 mg/day [38, 39] and tolerability 
within the dose range of 1.5–12.0 mg/day [37–39]. 
There do not appear to be clinically relevant 
adverse effects of cariprazine on metabolic variables, 
prolactin, or the ECG QT interval. In the fixed-
dose study of cariprazine that tested 1.5, 3.0, and 
4.5 mg/day, the most commonly encountered 
adverse events were insomnia, extrapyramidal 
disorder, sedation, akathisia, nausea, dizziness, 
vomiting, anxiety, and constipation [38]. However, 
the differences in incidence versus placebo for these 
events were generally small. Detailed data regarding 
tolerability for doses greater than 4.5 mg/day, as used 
in the two positive phase 3 studies [39], have not 
yet been presented. Additional controlled long-term 
data is desirable to further characterize any longer-
term treatment-related changes in body weight, 
metabolic variables, and movement disorders.
A recommendation in product labeling for 
dose titration will likely mirror that used in the 
Adv Ther (2013)  30(2):114–26. 123
clinical trials, otherwise dosing is once daily 
without regard to meals. When comparing 
cariprazine with the commercially available, 
“metabolically-friendly,” second-generation 
antipsychotics, cariprazine most resembles 
aripiprazole (see Table 3) [38, 43–48].
Cariprazine is a potential alternative 
to aripiprazole [44, 49]. Although both 
cariprazine and aripiprazole are dopamine 
receptor partial agonists, cariprazine has 
a different receptor binding profile, with 
greater affinity for the dopamine D3 receptor 
as the main distinguishing feature. Whether 
this would be clinically relevant requires 
additional randomized controlled trials that are 
specifically designed and powered to contrast 
cariprazine with aripiprazole at optimal doses. 
Regarding the latter, it is unclear which doses 
of cariprazine would offer the best balance in 
terms of efficacy and tolerability. Moreover, 
the presence of the active metabolite, 
didesmethyl-cariprazine, with a half-life of 3 
weeks, provides an opportunity to test different 
dosing regimens, such as once-weekly oral 
administration. 
Whether or not cariprazine has pro-cognitive 
effects and/or ameliorates negative symptoms in 
persons with schizophrenia through action at 
Table 3  Highlights of dierences and similarities among cariprazine, ziprasidone, aripiprazole, iloperidone, asenapine, and 
lurasidone regarding their adverse event proles in acute schizophrenia in adults as reported in product labeling and available 












































AE – somnolence, 
NNH
20–50 (sedation) 15 20 16 17 10
AE – akathisia, 
NNH
20–34 100 25 Rate lower than 
placebo
33 10
NNH weight gain 
≥7% 
12–35 17 20 12 35 67
Prolactin warning? No Yes No Yes Yes Yes
QT warning? No Yes No Yes Yes No
Adapted with permission om Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv 
er. 2012;29:815–25 [48]
AE adverse event, NNH number needed to harm
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the dopamine D3 or serotonin 5-HT1A receptor 
will require specifically designed clinical trials. 
Cost will likely be a consideration given 
the availability of generic second-generation 
antipsychotics, including the future emergence 
of generic formulations of aripiprazole. 
The availability of a long-acting injectable 
formulation of aripiprazole may also factor into 
clinical decision making [50]. 
At present, available data are limited to trials 
with constrained inclusion/exclusion criteria 
that can limit their generalizability. Moreover, 
so far, none of the efficacy studies have been 
published in peer-reviewed journals, and so the 
data presented must be considered preliminary 
and subject to revision. 
Logical candidates for cariprazine treatment 
would be adults with schizophrenia for whom 
metabolic or cardiovascular risk is a concern, 
and for whom weight gain is to be minimized or 
avoided. Patients who are sensitive to akathisia, 
nausea, and parkinsonism will need to be 
monitored for these adverse drug reactions. 
CONCLUSIONS
If commercialized, cariprazine will be a new 
treatment option for schizophrenia. Based 
on the short-term studies conducted by the 
manufacturer, efficacy was established in the dose 
range of 1.5–9.0 mg/day and tolerability within 
the dose range of 1.5–12.0 mg/day. There do not 
appear to be clinically relevant adverse effects of 
cariprazine on metabolic variables, prolactin, or 
the ECG QT interval. In the fixed-dose study of 
cariprazine that tested 1.5, 3.0, and 4.5 mg/day, 
the most commonly encountered adverse events 
were insomnia, extrapyramidal disorder, sedation, 
akathisia, nausea, dizziness, vomiting, anxiety, 
and constipation. However, the differences in 
incidence versus placebo for these events were 
generally small. Information from a 48-week, 
open-label study provides tolerability data that is 
generally consistent with that from the available 
information from the short-term registration 
trials. Additional clinical trials are underway 
for the use of cariprazine in relapse prevention 
in schizophrenia, and in patients with bipolar 
disorder and major depressive disorder. 
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